Loryna Kit
Product Images NDC 63629-2336

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Loryna (NDC 63629-2336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

Figure 1 shows the VTE risk comparison of Drospirenone and Ethinyl Estradiol with LNG-Containing COCs. The text refers to multiple studies and their corresponding hazard ratios, odds ratios, and study designs. The text also mentions the names of some of the studies, including Ingonix, EURAS, and MEGA. Overall, the text appears to be a summary of a research article or report on the subject of contraception and VTE risk.*

FDA Label Image

Figure 2 (Image 02)

The text provides a figure titled "Likelihood of Developing a VTE" that compares the number of women with a blood clot out of 10,000 women years between different groups such as non-pregnant, non-COC user, COC-User, pregnancy, and postpartum up to 12 weeks. The text also includes a note that the pregnancy data is based on the actual duration of pregnancy and assumes that pregnancy lasts nine months, with a rate of 710 27 per 10,000 WY.*

FDA Label Image

Structure Formula (Image 03)

Ethinyl estradiol and Drospirenone are two active ingredients commonly found in birth control pills. Ethinyl estradiol is a synthetic form of estrogen, a hormone produced by the ovaries. Drospirenone is a progestin, a synthetic form of progesterone, another female hormone. Together, they work to prevent pregnancy by thickening cervical mucus, which makes it difficult for sperm to reach an egg, and by suppressing ovulation, which is the release of an egg from the ovaries. These drugs are used in various combinations and doses, depending on the type of birth control pill prescribed by a healthcare provider.*

FDA Label Image

Figure (Image 04)

This text appears to provide information about different levels of pregnancy rates among women and various methods of birth control. The rates range from fewer than one pregnancy per 100 women in a year to 85 or more pregnancies per 100 women in a year. The text lists different birth control methods, including injections, intrauterine devices, sterilization, birth control pills, skin patches, vaginal rings with hormones, condoms, diaphragms, spermicide, and withdrawal. Additionally, the text suggests not having sex during the most fertile days of the monthly cycle as another possible method.*

FDA Label Image

Figure 3 (Image 06)

This text provides information on the likelihood of developing a serious blood clot for non-pregnant women who are either cOe users or non-cOe users. The data also includes the number of women out of 10,000 who developed a blood clot during pregnancy and postpartum (12 weeks only). The information is presented in a numerical format.*

FDA Label Image

Label (Lbl636292336)

This is a description of a medication package containing Drospirenone and Ethinyl Estradiol tablets. The package contains 24 peach tablets with 3mg drospirenone, 0.02mg ethinyl estradiol, and 4 white inert tablets. It is not child resistant, so it is recommended to keep it out of reach of children. The medication should be stored between 20°C to 25°C (68°F to 77°F). The NDC number for the medication is 63629-2336-1. There are 84 tablets in total, which are distributed in three blister cards of 28 tablets each.*

FDA Label Image

Loryna-new-blister (Loryna New Blister)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.